BNOX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	16 634.00
Średni wolumen	120 073
Kapitalizacja rynkowa	10.28M
EPS	$0 ( 2024-05-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.00600 (0.62%)

Bionomics Limited Korelacja

10 Najbardziej pozytywne korelacje
GETVV	0.97
LVTX	0.951
MMAT	0.946
KTTA	0.944
VIH	0.936
OP	0.936
GRNV	0.935
RMRM	0.934
DRUG	0.932
SYBT	0.932

10 Najbardziej negatywne korelacje
TIPT	-0.948
LYTS	-0.945
JMPNZ	-0.94
LRFC	-0.938
GLLI	-0.934
THCP	-0.932
NKSH	-0.932
WYNN	-0.93
LMB	-0.928
HAIA	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bionomics Limited Finanse

Annual	2023
Przychody:	$432 666
Zysk brutto:	$-12.63M (-2 919.26 %)
EPS:	$-2.60

FY	2023
Przychody:	$432 666
Zysk brutto:	$-12.63M (-2 919.26 %)
EPS:	$-2.60

FY	2022
Przychody:	$4.18M
Zysk brutto:	$-6.87M (-164.21 %)
EPS:	$-2.49

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.50

Financial Reports:

No articles found.

Bionomics Limited

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.